A growth-hormone-releasing hormone (GHRH) analog, FDA-approved as Egrifta for HIV-associated fat accumulation and studied for its effect on visceral fat.
Reviewed for accuracy · Last reviewed July 7, 2026Tesamorelin is a synthetic form of GHRH that prompts the pituitary gland to release its own growth hormone, rather than replacing growth hormone directly. It's approved (as Egrifta) to reduce excess abdominal fat in people with HIV-associated lipodystrophy, and it's studied more broadly for its effect on visceral fat: the deeper fat around the organs.
It's given as a daily subcutaneous injection. Because it works by nudging the body's own hormone production, effects tend to build gradually and typically reverse after the compound is discontinued, so any change isn't usually maintained without continued use.
The pivotal HIV trials used 2 mg (2000 mcg) subcutaneously once daily. The reformulated EGRIFTA SV label specifies 1.4 mg once daily, so the right figure depends on the formulation.
Read the full Tesamorelin dosage guide →Common label reactions include arthralgia (joint pain), injection-site reactions, peripheral edema, and myalgia. Because it raises IGF-1, the label also flags glucose intolerance and fluid retention.
Read the full Tesamorelin side effects guide →Keep unmixed vials refrigerated and away from light. Tesamorelin is less stable once mixed than the GLP-1 peptides. Most research reports store it refrigerated for only about two weeks. See the full storage & safety guide for handling and disposal basics.
This page is an independent educational reference and is not medical advice. Talk to a doctor before starting any compound.